# Pharmacokinetics and Safety/Tolerability Profiles of DA-5206 Versus Talion® Under Fasting and Fed States in Healthy Male Subjects

> **NCT03200496** · PHASE1 · COMPLETED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DA-5206(Fasting)
- **DRUG:** DA-5206(Fed)
- **DRUG:** TALION®

## Key facts

- **NCT ID:** NCT03200496
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-29
- **Primary completion:** 2017-06-29
- **Final completion:** 2017-06-29
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03200496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03200496, "Pharmacokinetics and Safety/Tolerability Profiles of DA-5206 Versus Talion® Under Fasting and Fed States in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03200496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*